# Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

> **NCT04741997** · EARLY_PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV
- BRAF V600 Mutation

## Interventions

- **DRUG:** Encorafenib Pill
- **DRUG:** Binimetinib Pill
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04741997
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2026-07-22
- **Final completion:** 2027-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04741997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04741997, "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04741997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*